Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Diagnosed as hypoactive delirium~* Informed consent given~Exclusion Criteria:~* Pregnancy~* Epilepsy~* M. Parkinson~* Lewy-body dementia~* Prolonged QT-time~* Known allergy to the medicinals used~* Renal replacement therapy~* Hepatic encephalopathy~* Hyperthyroid~* Glaucoma~* Previous suicide attempts~* Syndrome of Gilles de la Tourette~* Patients which cannot receive the medication oral or through a nasogastric tube

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): No intervention
- 2 (Type: EXPERIMENTAL): Methylphenidate
- 3 (Type: EXPERIMENTAL): Rivastigmine
- 4 (Type: EXPERIMENTAL): Haloperidol

Based on this trial design, predict the completion outcome and termination type (if applicable).